$64.46 $4.28 (7.1%)

04:00 PM EST on 12/06/19

Sage Therapeutics, Inc. (NASDAQ:SAGE)

CAPS Rating: 2 out of 5

Current Price $64.46 Mkt Cap $3.3B
Open $63.19 P/E Ratio 0.00
Prev. Close $60.18 Div. (Yield) $0.00 (0.0%)
Daily Range $61.02 - $65.90 Volume 5,586,167
52-Wk Range $56.50 - $193.56 Avg. Daily Vol. 911,570

Caps

How do you think NASDAQ:SAGE will perform against the market?

Add Stock to CAPS Watchlist

All Players

36 Outperform
6 Underperform
 

All-Star Players

12 Outperform
3 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:SAGE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

GNUBEE (< 20)
Submitted November 10, 2014

fist pick in a few years, following Porte to get my feet wet...

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:SAGE VS S&P 500 (SPY)

NASDAQ:SAGE Summary

Fools bullish on NASDAQ:SAGE are also bullish on:

Fools bearish on NASDAQ:SAGE are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about SAGE.

Recs

0
Member Avatar Bigsef77 (69.72) Submitted: 1/4/2019 2:43:04 PM : Outperform Start Price: $170.36 NASDAQ:SAGE Score: -74.14

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
[Business Wire]
Business Wire•January 4, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 15,000 shares of its common stock to five new employees under Sage’s 2016 Inducement Equity Plan.

The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

The options have an exercise price of $89.45 per share, which is equal to the closing price of Sage’s common stock on January 2, 2019. Each option will vest and become exercisable as to 25% of the shares on the first anniversary of the recipient’s start date, and will vest and become exercisable as to the remaining 75% of the shares in 36 equal monthly installments following the first anniversary, in each case, subject to each such employee’s continued employment with Sage on such vesting dates. The options are subject to the terms and conditions of Sage’s 2016 Inducement Equity Plan, and the terms and conditions of a stock option agreement covering the grant.

Recs

0
Member Avatar XMFRendezvous (93.36) Submitted: 2/9/2018 3:08:16 AM : Outperform Start Price: $159.02 NASDAQ:SAGE Score: -80.19

Sage Therapeutics has had an incredible few months as the FDA has fast tracked some of their treatments. Sage business seems to be catching some headwinds and they are looking to offer more stock to continue to fuel their business. Many of their drugs have to do with mental disorders such a depression, and where I do question the merits of drugs for mental illness I acknowledge the science behind it and unfortunately I do think that mental health will only continue to be more of an issue in the future.

I always have trouble writing about Biotechs because I really don't know what I am taking about but, many biotech analysts are high on this stock. Sage looks to be like one of the top programmers.

Recs

0
Member Avatar TMFGBudwell (22.21) Submitted: 12/7/2017 5:33:35 PM : Outperform Start Price: $158.97 NASDAQ:SAGE Score: -78.27

Multiple product candidates in development.

Leaderboard

Find the members with the highest scoring picks in SAGE.

Score Leader

BeatdaMarket

BeatdaMarket (59.35) Score: +160.45

The Score Leader is the player with the highest score across all their picks in SAGE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
WildShaman 96.39 7/9/2018 Underperform 5Y $160.36 -59.80% +13.85% +73.65 0 Comment
PHIL1120 64.14 8/13/2019 Underperform 1Y $168.00 -61.63% +9.42% +71.05 0 Comment
zzlangerhans 99.72 9/11/2017 Underperform 1Y $88.32 -27.02% +26.94% +53.95 0 Comment
Eli4Prez 77.41 11/22/2017 Underperform 3Y $95.95 -32.82% +21.12% +53.94 0 Comment
jeepdrew222 66.16 5/16/2016 Outperform 5Y $32.17 +100.37% +53.62% +46.76 0 Comment
TSIF 99.97 8/9/2016 9/20/2017 Outperform 3Y $37.05 +73.98% +44.43% +29.55 0 Comment
investat < 20 9/12/2016 Outperform NS $38.35 +68.08% +48.24% +19.84 0 Comment
GNUBEE < 20 11/10/2014 Outperform 5Y $37.13 +73.61% +54.51% +19.09 1 Comment
portefeuille 98.38 11/10/2014 Outperform 5Y $37.28 +72.90% +54.60% +18.30 0 Comment
portefeuille2 99.12 12/24/2014 Outperform 5Y $38.07 +69.32% +51.19% +18.13 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SAGE.